Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK157D1 in Advanced Solid Tumors
NCT07847281Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK157D1 in solid tumor, sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Adverse Events at 90 days. Started Sep 2026; status: recruiting.
02
Drugs
AK157D1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07847281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847281.